Strategic collaborations Ventus has active high-profile partnerships, including a multi-year collaboration and license with Genentech to discover and optimize novel small-molecule candidates using the ReSOLVE platform, signaling strong potential for co-development and licensing discussions.

Clinical-stage momentum With two Phase 2 small-molecule programs advancing in immunological, inflammatory, and neurological disorders, there is an opportunity to position your services or therapies as complementary or to explore strategic financing, research support, or optional pipeline expansion.

Discovery platform ReSOLVE enables discovery in challenging targets and novel pockets, offering a compelling angle for service partnerships around structure-based drug design, SAR optimization, and computational chemistry collaborations.

Geographic expansion Recent Montreal expansion and a U.S. base suggest openness to regional partnerships, CRO collaborations, and academic-industrial joint ventures, particularly in North America where talent and facilities are aligned.

Strategic fundraising Active investor engagement and conference appearances indicate readiness for strategic investments, co-development funding, or grant-supported research programs that accelerate program timelines and de-risk early-stage collaborations.